

Adrian F Ochsenbein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030246/publications.pdf>

Version: 2024-02-01

101
papers

11,037
citations

53751

45
h-index

34964

98
g-index

103
all docs

103
docs citations

103
times ranked

14709
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 405-415.	2.0	8
2	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 179-188.	3.2	16
3	Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. <i>Cell Reports</i> , 2021, 34, 108663.	2.9	21
4	LIGHT/LTÎ²R signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. <i>Nature Communications</i> , 2021, 12, 1065.	5.8	9
5	A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. <i>Modern Pathology</i> , 2021, 34, 1333-1344.	2.9	22
6	Abstract PO-039: Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy approach for glioblastoma multiforme. , 2021, , .		0
7	Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 663406.	1.3	14
8	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-â€Small-Cell Lung Cancerâ€”A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880.	0.8	183
9	Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. <i>JCI Insight</i> , 2021, 6, .	2.3	15
10	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma. <i>Cancer Cell</i> , 2020, 37, 621-622.	7.7	4
11	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. <i>Nature Medicine</i> , 2020, 26, 1459-1467.	15.2	122
12	TNIK signaling imprints CD8+ T cell memory formation early after priming. <i>Nature Communications</i> , 2020, 11, 1632.	5.8	16
13	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9016-9016.	0.8	27
14	Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry. <i>Swiss Medical Weekly</i> , 2020, 150, w20176.	0.8	11
15	The imaging substudy of the randomized ARTE trial: MRI and 18FET PET associations with overall survival benefit from bevacizumab in elderly patients with newly diagnosed IDH wildtype glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2520-2520.	0.8	0
16	CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2379-2392.	3.3	29
17	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	6.3	2,347
18	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , 2019, 3, 3674-3687.	2.5	40

#	ARTICLE	IF	CITATIONS
19	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	2.6	37
20	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019, 21, 185-196.	2.3	38
21	T-cellâ€“Secreted TNFÎ± Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. <i>Cancer Research</i> , 2019, 79, 346-359.	0.4	45
22	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123.	0.5	21
23	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. <i>Oncolimmunology</i> , 2018, 7, e1365997.	2.1	2
24	CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. <i>Blood</i> , 2017, 130, 297-309.	0.6	37
25	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Nonâ€“Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. <i>Clinical Lung Cancer</i> , 2017, 18, 303-309.	1.1	13
26	CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2017, 214, 359-380.	4.2	125
27	TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. <i>Nature Communications</i> , 2016, 7, 13151.	5.8	76
28	Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 18-25.	1.6	18
29	CD127+ innate lymphoid cells are dysregulated in treatment naive acute myeloid leukemia patients at diagnosis. <i>Haematologica</i> , 2015, 100, e257-e260.	1.7	69
30	A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1054-1059.	0.6	15
31	Tyrosine kinase inhibitorâ€“induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. <i>Science Translational Medicine</i> , 2015, 7, 298ra119.	5.8	71
32	CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. <i>Leukemia Research</i> , 2015, 39, 749-756.	0.4	48
33	Complete pain relief after bevacizumab in a patient with neurofibromatosis type 2. <i>Acta OncolÃ³gica</i> , 2015, 54, 280-283.	0.8	2
34	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. <i>Clinical Lung Cancer</i> , 2015, 16, 358-365.	1.1	14
35	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1651-1658.	5.1	170
36	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. <i>Lancet</i> , The, 2015, 386, 1049-1056.	6.3	316

#	ARTICLE	IF	CITATIONS
37	Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. <i>Leukemia</i> , 2015, 29, 1781-1785.	3.3	26
38	Regulation of hematopoietic and leukemic stem cells by the immune system. <i>Cell Death and Differentiation</i> , 2015, 22, 187-198.	5.0	195
39	IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. <i>Journal of Clinical Investigation</i> , 2015, 125, 2579-2591.	3.9	80
40	TREM-1 Deficiency Can Attenuate Disease Severity without Affecting Pathogen Clearance. <i>PLoS Pathogens</i> , 2014, 10, e1003900.	2.1	116
41	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 141-145.	1.4	52
42	Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 381-394.	2.0	84
43	Microbiota-Derived Compounds Drive Steady-State Granulopoiesis via MyD88/TICAM Signaling. <i>Journal of Immunology</i> , 2014, 193, 5273-5283.	0.4	202
44	Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells. <i>Cell Stem Cell</i> , 2014, 14, 460-472.	5.2	174
45	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- γ . <i>Journal of Experimental Medicine</i> , 2013, 210, 605-621.	4.2	72
46	Dendritic Cell-Based Immunotherapy for Myeloid Leukemias. <i>Frontiers in Immunology</i> , 2013, 4, 496.	2.2	37
47	Interferons in hematopoiesis and leukemia. <i>Oncolmmunology</i> , 2013, 2, e24572.	2.1	6
48	Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7503-7503.	0.8	9
49	From "magic bullets" to specific cancer immunotherapy. <i>Swiss Medical Weekly</i> , 2013, 143, w13734.	0.8	10
50	Modulating CD27 signaling to treat cancer. <i>Oncolmmunology</i> , 2012, 1, 1604-1606.	2.1	24
51	CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth. <i>Cancer Research</i> , 2012, 72, 3664-3676.	0.4	133
52	Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. <i>Case Reports in Oncology</i> , 2012, 5, 280-289.	0.3	8
53	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. <i>Oncology Reports</i> , 2012, 28, 654-658.	1.2	29
54	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). <i>Lung Cancer</i> , 2012, 78, 239-244.	0.9	33

#	ARTICLE	IF	CITATIONS
55	CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. <i>Journal of Clinical Investigation</i> , 2012, 122, 624-638.	3.9	84
56	Long term survival after trimodal therapy in malignant pleural mesothelioma. <i>Swiss Medical Weekly</i> , 2012, 142, w13686.	0.8	8
57	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	0.8	38
58	Destruction of Lymphoid Organ Architecture and Hepatitis Caused by CD4+ T Cells. <i>PLoS ONE</i> , 2011, 6, e24772.	1.1	15
59	Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 103, 343-351.	1.4	21
60	Chronic myelogenous leukemia maintains specific CD8 ⁺ T cells through IL-7 signaling. <i>European Journal of Immunology</i> , 2010, 40, 2720-2730.	1.6	8
61	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. <i>Nature Medicine</i> , 2010, 16, 339-345.	15.2	122
62	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2712-2718.	0.8	389
63	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2010, 28, e696-e697.	0.8	0
64	CTL induction by cross-priming is restricted to immunodominant epitopes. <i>European Journal of Immunology</i> , 2009, 39, 704-716.	1.6	18
65	Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. <i>Blood</i> , 2009, 113, 4681-4689.	0.6	24
66	Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. <i>Blood</i> , 2009, 114, 1528-1536.	0.6	250
67	CD4 ⁺ T cell help improves CD8 ⁺ T cell memory by retained CD27 expression. <i>European Journal of Immunology</i> , 2008, 38, 1847-1856.	1.6	34
68	Natural antibodies target virus-antibody complexes to organized lymphoid tissue. <i>Autoimmunity Reviews</i> , 2008, 7, 480-486.	2.5	37
69	Early Clinical Trial Experience with Vaccine Therapies in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S20-S27.	1.1	10
70	Decreased Tumor Surveillance after Adoptive T-Cell Therapy. <i>Cancer Research</i> , 2007, 67, 7467-7476.	0.4	18
71	PD-1 Signaling on Chronic Myeloid Leukemia-Specific T Cells Results in T Cell Exhaustion and Disease Progression.. <i>Blood</i> , 2007, 110, 2923-2923.	0.6	0
72	Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. <i>Blood</i> , 2006, 108, 3406-3413.	0.6	67

#	ARTICLE	IF	CITATIONS
73	Elimination of chronic viral infection by blocking CD27 signaling. <i>Journal of Experimental Medicine</i> , 2006, 203, 2145-2155.	4.2	99
74	Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. <i>European Journal of Immunology</i> , 2005, 35, 3229-3239.	1.6	42
75	Immunological ignorance of solid tumors. <i>Seminars in Immunopathology</i> , 2005, 27, 19-35.	4.0	44
76	CD27 Expression Promotes Long-Term Survival of Functional Effector Memory CD8+ Cytotoxic T Lymphocytes in HIV-infected Patients. <i>Journal of Experimental Medicine</i> , 2004, 200, 1407-1417.	4.2	113
77	Outcome of the antibody response: a question of antigen dose and distribution. <i>Trends in Immunology</i> , 2004, 25, 165-166.	2.9	4
78	Quantification of fetomaternal hemorrhage by fluorescence microscopy is equivalent to flow cytometry. <i>Transfusion</i> , 2002, 42, 947-953.	0.8	22
79	Principles of tumor immunosurveillance and implications for immunotherapy. <i>Cancer Gene Therapy</i> , 2002, 9, 1043-1055.	2.2	93
80	Neutralizing antiviral antibody responses. <i>Advances in Immunology</i> , 2001, 79, 1-53.	1.1	74
81	LEFLUNOMIDE-MEDIATED SUPPRESSION OF ANTIVIRAL ANTIBODY AND T CELL RESPONSES: DIFFERENTIAL RESTORATION BY URIDINE1. <i>Transplantation</i> , 2001, 72, 712-719.	0.5	15
82	Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. <i>Nature</i> , 2001, 411, 1058-1064.	13.7	469
83	Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells. <i>Journal of Immunology</i> , 2001, 166, 3678-3687.	0.4	82
84	Natural antibodies and complement link innate and acquired immunity. <i>Trends in Immunology</i> , 2000, 21, 624-630.	7.5	479
85	Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease. <i>Journal of Experimental Medicine</i> , 2000, 191, 795-804.	4.2	251
86	Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 13263-13268.	3.3	187
87	Correlation of T Cell Independence of Antibody Responses with Antigen Dose Reaching Secondary Lymphoid Organs: Implications for Splenectomized Patients and Vaccine Design. <i>Journal of Immunology</i> , 2000, 164, 6296-6302.	0.4	76
88	FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory. <i>Journal of Immunology</i> , 2000, 164, 5761-5770.	0.4	349
89	Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions. <i>Molecular and Cellular Biology</i> , 2000, 20, 5363-5369.	1.1	125
90	Viral persistence in vivo through selection of neutralizing antibody-escape variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 2749-2754.	3.3	142

#	ARTICLE	IF	CITATIONS
91	Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11964-11969.	3.3	106
92	Protective T Cell-Independent Antiviral Antibody Responses Are Dependent on Complement. Journal of Experimental Medicine, 1999, 190, 1165-1174.	4.2	149
93	A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9293-9298.	3.3	66
94	Immune surveillance against a solid tumor fails because of immunological ignorance. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2233-2238.	3.3	422
95	Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunological Reviews, 1999, 169, 45-54.	2.8	85
96	A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion. European Journal of Immunology, 1999, 29, 2981-2987.	1.6	20
97	Control of Early Viral and Bacterial Distribution and Disease by Natural Antibodies. Science, 1999, 286, 2156-2159.	6.0	822
98	IgD can largely substitute for loss of IgM function in B cells. Nature, 1998, 393, 797-801.	13.7	126
99	T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nature Medicine, 1998, 4, 945-948.	15.2	46
100	Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism: Clinical and Experimental, 1994, 43, 697-705.	1.5	86
101	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer – A Multicentre Single-Arm Phase II Trial. SSRN Electronic Journal, 0, , .	0.4	0